HonCode

Go Back   HER2 Support Group Forums > Breast Cancer Meeting Highlights
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Breast Cancer Meeting Highlights News fro recent ASCO and San Antonio Meetings

Reply
 
Thread Tools Display Modes
Old 05-18-2014, 01:56 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) re

Comorbidity, metastases, and survival in women with metastatic breast cancer (mBC) receiving HER2-targeted agents (H2Ts).

Abstract No:
e11574
Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2014 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Author(s): Nicole Meyer, Yanni Hao, Xue Song, William M. Johnson, Nianwen Shi, Jaqueline Willemann Rogerio, Denise A. Yardley; Truven Health Analytics, Inc., Cambridge, MA; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN
Abstract Disclosures

Abstract:

Background: Little information on survival is available for subgroups of HER2+ mBC patients. Study objectives were to compare clinical histories, progression, and survival of mBC patients treated with H2Ts, by de novo vs recurrent status , ER+ status, and age. Methods: Women ≥ 18 years with Stage IV mBC (index) during 2008-2012 and treated with H2Ts were selected from a large claims database and followed until death or end of data. Patients were stratified by ER+ status, de novo (≤90 days between initial BC diagnosis and index) vs recurrent (>90 days between initial BC diagnosis and index), and ages 18-44, 45-64, or 65+. Relative risk of progression and death were evaluated among the subset of patients with mortality data. Results: Of 2,629 eligible patients, 52% were ER+, 37% de novo, 15% 18-44, 69% 45-64 and 16% 65+. Median follow-up was longer for ER+ vs ER-, de novo vs recurrent, and decreased with age. Baseline comorbid conditions were lower for ER+ vs ER-, higher for de novo vs recurrent and increased with age. ER+ patient had fewer index metastases, were less likely to have liver, lung and brain but more likely to have bone metastases vs ER-. De novo had more index metastases sites, but lower rates of brain and lung metastases vs recurrent. Among the 32% of patient with mortality information, progression was similar by ER+ status, lower in de novo vs recurrent, and lowest for ages 45-64, while mortality rates were higher for ER- vs ER+ (33% vs 19%), recurrent vs de novo (29% vs 18%) and increased with age (18% 18-44, 23% 45-64, 40% 65+). Multivariate analysis suggested the risk of progression was 30% lower among ER+ patients vs ER- , 32% lower for de novo vs recurrent, and similar across age groups. The risk of death was 52% lower for ER+ vs ER-, 35% lower for de novo vs recurrent, and increased with age. Conclusions: Among mBC patients treated with H2Ts, ER+ status and younger age were associated with lower comorbidity, fewer sites of metastases at index and decreased risk of death during follow-up. De novo patients presented with more comorbid conditions and sites of metastases at index, but had lower risk of progression or death during follow-up vs. recurrent patients.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 05:06 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter